Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer - Beer, T M; Kwon, E D; Drake, C G (J Clin Oncol, 2017)